What Is Apheresis

Apheresis is a medical procedure in which blood is drawn from the body, passed through a device that separates and removes specific components (such as plasma, lipids, antibodies, or white blood cells), and then returned to the patient. The term comes from the Greek word for "to take away." Different forms of apheresis target different blood fractions, making it a flexible platform for addressing conditions ranging from dangerously elevated cholesterol to autoimmune disease.

Blood composition changes with age. Circulating levels of inflammatory cytokines, oxidized lipoproteins, misfolded proteins, and senescence-associated factors accumulate over decades. Research in parabiosis (connecting the circulatory systems of old and young animals) has shown that simply diluting or replacing old plasma with young plasma or albumin can rejuvenate tissue function in aged mice. This line of inquiry has renewed interest in apheresis as a way to modify the blood environment directly.

For longevity, the appeal is straightforward: if the aging blood milieu contributes to organ decline, then periodically filtering out harmful components could slow that decline. Lipid apheresis has a long clinical track record for lowering Lp(a) and LDL in patients who do not respond adequately to statins. The broader question now is whether removing inflammatory mediators, autoantibodies, and other age-related plasma factors can meaningfully extend healthspan. This remains an active area of investigation, with clinical interest outpacing published human trial data.

During an apheresis session, blood exits through a venous catheter and enters an extracorporeal circuit. A cell separator (centrifugal or membrane-based) divides blood into its constituent layers: red cells, white cells, platelets, and plasma. Depending on the clinical goal, one or more of these fractions is selectively removed or filtered, and the remaining components are recombined with replacement fluid (saline, albumin, or donor plasma) before being returned to the patient.

Lipid apheresis uses adsorption columns or precipitation methods to pull LDL cholesterol and Lp(a) from plasma. Some columns use dextran sulfate or heparin to bind apolipoprotein B-containing particles selectively. This can lower LDL by 60 to 75 percent in a single session, though levels rebound over the following one to two weeks as the liver resynthesizes lipoproteins. For inflammatory or autoimmune apheresis, the mechanism is different: immunoadsorption columns bind immunoglobulins or immune complexes, depleting the pathogenic antibodies driving tissue damage.

In the longevity context, therapeutic plasma exchange (a form of apheresis) aims to dilute the entire soluble plasma proteome. Animal studies have demonstrated that neutral plasma exchange, replacing old plasma with saline and albumin, can improve muscle repair, reduce liver fibrosis markers, and enhance hippocampal neurogenesis in aged mice. The hypothesis is that removing accumulated pro-aging factors (such as CCL11, beta-2-microglobulin, and certain complement proteins) resets the signaling environment that tissues are bathed in, allowing regenerative pathways to reactivate.

An apheresis session begins with the placement of two intravenous lines, typically one in each arm, though some setups use a single dual-lumen catheter. Blood flows out through one line, passes through the apheresis machine (which may use centrifugation, filtration membranes, or adsorption columns depending on the type), and returns through the other line. The process is continuous, meaning blood is being drawn, filtered, and returned simultaneously.

During the session, you remain reclined in a chair or bed. Most people read, watch screens, or sleep. A citrate anticoagulant is added to prevent clotting in the circuit, which can cause a tingling sensation around the lips and fingertips; calcium supplementation during the session typically manages this. Vital signs are monitored throughout. After the session, mild fatigue and lightheadedness are common for a few hours. Most patients return to normal activities the same day.

For lipid apheresis, you can expect an immediate and measurable drop in LDL and Lp(a) levels on post-procedure blood draws. For plasma exchange, improvements in symptoms (for autoimmune conditions) may take one to several sessions. In the longevity context, subjective improvements in energy and cognition have been reported anecdotally, but objective biomarker changes are the more reliable outcome to track.

Session length typically ranges from two to four hours. The frequency depends entirely on the indication. For familial hypercholesterolemia, lipid apheresis is commonly performed every one to two weeks on an ongoing basis, because lipid levels rebound between sessions. Autoimmune indications may involve a concentrated series of five to seven sessions over two weeks, followed by a maintenance schedule.

For longevity-oriented plasma exchange, there is no established protocol. Some practitioners perform a series of three to five sessions over several weeks, then reassess biomarkers before deciding on maintenance frequency. Others recommend quarterly sessions. Without controlled trial data defining an optimal schedule, the approach is empirical and should be guided by measurable changes in the specific biomarkers being targeted.

Apheresis is among the more expensive longevity interventions. A single session at a clinic ranges from approximately $2,000 to $10,000 depending on the type of apheresis, the geographic location, and whether specialized adsorption columns are used. Lipid apheresis with proprietary columns tends toward the higher end of this range. Insurance typically covers apheresis for approved medical indications (familial hypercholesterolemia with documented statin failure, certain autoimmune diseases) but does not cover off-label longevity use.

Because the procedure requires repeated sessions to maintain its effects, the annual cost for a longevity-focused protocol can accumulate to tens of thousands of dollars. This makes it accessible primarily to those who can absorb the expense out of pocket, and it underscores the importance of confirming through biomarker testing that the intervention is producing meaningful, measurable changes.

Apheresis has a robust evidence base for its established medical indications. Lipid apheresis for familial hypercholesterolemia is supported by decades of clinical use and multiple observational studies showing reduced cardiovascular events in patients with refractory hyperlipidemia. The American Society for Apheresis publishes evidence-based guidelines categorizing indications by strength of evidence, and conditions like thrombotic thrombocytopenic purpura and Guillain-Barré syndrome carry strong recommendations.

The longevity application is far less mature. The foundational parabiosis studies in mice, particularly work showing that diluting old plasma with neutral solutions (saline and albumin) rejuvenates multiple organ systems, have generated significant scientific interest. A small human pilot study of therapeutic plasma exchange in older adults has been reported, measuring changes in proteomic markers, but large, controlled trials have not been completed. The durability of any anti-aging effect, optimal frequency, and long-term safety in otherwise healthy older adults remain open questions. The gap between animal model results and validated human longevity outcomes is substantial, and the current clinical use for aging is largely practitioner-driven rather than guideline-supported.

Apheresis carries procedure-related risks including hypotension, allergic reactions to replacement fluids, citrate-induced hypocalcemia (tingling, muscle cramps), infection at catheter sites, and transient coagulation changes. Repeated sessions can deplete immunoglobulins, clotting factors, and other beneficial plasma proteins, potentially increasing susceptibility to infections. The procedure is contraindicated in patients with active sepsis, severe hemodynamic instability, or certain coagulation disorders. When used off-label for longevity, the risk-benefit calculus is less defined because the expected benefits have not been quantified in controlled human trials. Anyone considering apheresis should have a thorough hematologic evaluation and ongoing monitoring by a physician experienced in extracorporeal therapies.